Drugs / Mulberry leaf extract
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07532135 | Oct 2025 → Sep 2026 overdue | hyperglycemia | Chulalongkorn University | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06488326 | Jul → Dec 2024 | — | Chulalongkorn University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT00795704 Comparator | Apr 2008 → May 2010 | type 2 diabetes mellitus | University of Mississippi Medical Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mulberry leaf extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06488326 ↗ |
| Route | Oral | “Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months” NCT00795704 ↗ |